[A18-34] Dolutegravir/rilpivirine (HIV infection) - Benefit assessment according to §35a Social Code Book V

Last updated 17.09.2018

Project no.:

Commission awarded on 24.05.2018 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:
Immune system and infections


HIV-1 infection in adults who are virologically-suppressed on a stable regimen for ≥ 6 months with no history of virological failure and no known or suspected resistance to any NNRTIs or INIs

Result of dossier assessment:

Without indication for a treatment switch: indication of lesser benefit; with indication for a treatment switch: added benefit not proven


After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Accompanying information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.

Federal Joint Committee (G-BA)

2018-12-06 A G-BA decision was published.

G-BA documents on this decision


Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.